A simple, fast, specific, stability-indicating, and precise reversed-phase liquid chromatographic method was developed for the determination of Cefdinir in its different dosage forms, i.e., capsules and suspensions. The method was developed and optimized by analyzing the placebo preparation, formulations, and degraded samples of the drug substance according to the International Conference on Harmonization. The proposed method can successfully separate the drug from degradation products formed under stress conditions along with pharmaceutical ingredients such as preservatives. The developed method was used successfully to determine Cefdinir in capsules and Insta-use suspensions. The developed method was found to be linear for a concentration range of 6-14 microg/mL. Average recoveries obtained with the method were 99.3 +/- 0.4 and 99.6 +/- 0.4% for Insta-use suspensions and capsules, respectively. The method was shown to be specific, precise, and robust.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
FL058, a novel β-lactamase inhibitor, increases the anti-Mycobacterium abscessus activity of imipenem.
Int J Antimicrob Agents
December 2024
Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; School of Medicine, Tongji University, Shanghai, China; Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address:
Background: β-lactams are crucial for anti-Mycobacterium abscessus complex (MABC) therapy. Treating infections is challenging since MABC produces a class A β-lactamase (Bla, which is capable of hydrolyzing β-lactams thus causing drug resistance. Diazabicyclooctane (DBO) β-lactamase inhibitors (BLIs) can inhibit Bla.
View Article and Find Full Text PDFBioequivalence of cefdinir dispersible tablets in healthy Chinese subjects under fasting and fed conditions: a single-centred, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, double-crossover trial.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
The Affiliated Panyu Central Hospital, Guangzhou Medical University, No. 8 Fuyu East Road, Guangzhou, Panyu District, China.
Cefdinir is a broad-spectrum antibiotic with good antibacterial activity against gram-positive and gram-negative bacteria and can be used for the treatment of various sensitive bacterial infections, such as community-acquired pneumonia, urinary tract infection and gonorrhoea. Herein, a single-centred, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, double-crossover trial with a 7-day washout was conducted to investigate the pharmacokinetics, bioequivalence and safety of cefdinir dispersible tablets and the reference formulation of cefdinir capsules in healthy Chinese volunteers. Fifty-six healthy subjects were recruited and randomly assigned to the fasting and fed groups.
View Article and Find Full Text PDFFormulation and optimization of surfactant-modified chitosan nanoparticles loaded with cefdinir for novel topical drug delivery: Elevating wound healing efficacy with enhanced antibacterial properties.
Int J Pharm
December 2024
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt. Electronic address:
Article Synopsis
- Burn wounds pose a major health issue globally, often complicated by bacterial infections that slow down healing and increase illness rates.
- This study focused on creating and optimizing chitosan nanoparticles loaded with Cefdinir (CFD-CSNPs) to improve the delivery and effectiveness of CFD for treating burn wounds, using a Box-Behnken Design method.
- The developed CFD-CSNPs showed promising results in particle size and entrapment efficiency, demonstrated effective antimicrobial properties, and significantly improved wound healing in both lab and animal models, highlighting their potential for treating burn injuries and infections.
The use of dual β-lactams to restore susceptibility of complex.
JAC Antimicrob Resist
October 2024
Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Background: The complex (MAC) are non-tuberculous mycobacteria responsible for chronic and debilitating conditions. Guideline-recommended therapy for MAC is a combination of clarithromycin/azithromycin, ethambutol and a rifamycin. However, culture conversion rates with this regimen are 67%.
View Article and Find Full Text PDFeffects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.
Microbiol Spectr
July 2024
Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Article Synopsis
- Non-tuberculosis mycobacteria (NTM), specifically a certain subspecies, are being increasingly identified as causes of pulmonary disease, but they show resistance to many antibiotics, making treatment challenging.* -
- In this study, researchers tested the effects of a novel antibiotic enhancer, xeruborbactam, when combined with five different β-lactam antibiotics and found that it significantly improved the effectiveness of several of these drugs against NTM.* -
- The combination of tebipenem and xeruborbactam showed particular promise, potentially offering a new all-oral treatment option for outpatient care of NTM pulmonary disease.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!